Scinai Immunotherapeutics Ltd. Sponsored ADR SCNI
1.55
(0.31)
(16.67%)
as of 25 Sep
- Market cap
- $1.2M
- P/E
- 0.0×
Follow SCNI
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | (1,794.09%) | 0.00% | 0.00% |
+8 more TTM periods Free account |
|
| 0.00% | 69.12% | 0.00% | 0.00% | ||
ROIC |
0.00% | (58.65%) | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 86.57% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | (24.60) | — | 0.00 | |
Free Cash Flow |
(6.62) | (9.32) | — | (9.62) | |
Capital Expenditures |
(0.13) | (0.03) | — | (0.03) | |
Piotroski F-Score |
— | 3.00 | — | — | |
| Other line items | |||||
Cash ROIC |
(43.68%) | (61.27%) | 0.00% | (103.34%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 3.52 | 0.00 | 0.00 | |
Inventory Turnover |
— | 0.00 | — | — | |
Average Days of Payables |
0.00 | 112.54 | 0.00 | 0.00 | |
Days of Inventory on Hand |
— | 0.00 | — | — | |
Tax Rate |
— | 0.00 | — | — | |
Research and Development Expense of Revenue |
— | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | — | — | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Interest Coverage |
— | 0.00 | — | — | |
Operating CF/Net income |
0.00 | (0.90) | — | 0.00 | |
Depreciation/Fixed assets |
0.16 | 0.21 | 0.00 | 0.28 | |
Capex/Depreciation |
(0.07) | (0.01) | — | (0.01) | |
Revenue per Share |
— | 0.00 | — | — | |
Operating CF per Share |
0.00 | (24.53) | — | 0.00 | |
Capex per Share |
0.00 | (0.07) | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
— | 0.00% | — | — |
Columns are period end dates